Physician profile
Charles E Weaver
NPI 1801899554
$2,182.46
in general payments reported to CMS, 2019-2025
14 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,552 · 2020: $70.78 · 2021: $161 · 2022: $17.13 · 2023: $137 · 2024: $110 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $1,387.89 | 2019-2025 | Vyrsa V1 |
| Spineology INC. | $268.63 | 2020-2025 | Optimesh Expandable Interbody Fusion System |
| Medtronic USA, INC. | $141.33 | 2019-2020 | |
| Nevro Corp. | $69.02 | 2021-2024 | Senza |
| Abbott Laboratories | $63.81 | 2023-2024 | Proclaim, Eterna |
| Cerapedics INC. | $56.09 | 2021 | |
| Medtronic, INC. | $38.59 | 2023-2024 | Intellis Adaptivestim |
| Nuvasive, INC. | $29.09 | 2019 | |
| Ossdsign USA Incorporated | $25.11 | 2025 | Ossdsign Catalyst |
| Portola Pharmaceuticals, LLC | $24.35 | 2020 | |
| Depuy Synthes Sales INC. | $23.35 | 2019 | |
| Heron Therapeutics, INC. | $20.02 | 2024 | Zynrelef |
| Baxter Healthcare | $18.05 | 2023 | Floseal |
| Bioventus LLC | $17.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.